Globus Medical (GMED) Q4 Earnings: What To Expect

Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after the bell. Here’s what to expect.

Globus Medical beat analysts’ revenue expectations by 3.7% last quarter, reporting revenues of $625.7 million, up 63.1% year on year. It was an exceptional quarter for the company, with a solid beat of analysts’ constant currency revenue and EPS estimates.

Is Globus Medical a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Globus Medical’s revenue to grow 4.1% year on year to $641.7 million, slowing from the 125% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.75 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Globus Medical has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Globus Medical’s peers in the medical devices & supplies - specialty segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Inspire Medical Systems delivered year-on-year revenue growth of 24.5%, beating analysts’ expectations by 0.9%, and Bausch + Lomb reported revenues up 9.1%, topping estimates by 1.8%. Inspire Medical Systems traded up 1.7% following the results.

Read our full analysis of Inspire Medical Systems’s results here and Bausch + Lomb’s results here.

Investors in the medical devices & supplies - specialty segment have had fairly steady hands going into earnings, with share prices down 2% on average over the last month. Globus Medical is down 8.5% during the same time and is heading into earnings with an average analyst price target of $97.85 (compared to the current share price of $84.57).

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.